Get the Stockscreener App
23.57
1.29%
0.30
After Hours:
23.25
-0.32
-1.36%
Xoma Royalty Corp stock is traded at $23.57, with a volume of 185.46K.
It is up +1.29% in the last 24 hours and down -12.02% over the past month.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
See More
Previous Close:
$23.27
Open:
$23.53
24h Volume:
185.46K
Relative Volume:
0.52
Market Cap:
$291.87M
Revenue:
$9.71M
Net Income/Loss:
$-29.96M
P/E Ratio:
-6.773
EPS:
-3.48
Net Cash Flow:
$-14.79M
1W Performance:
-5.42%
1M Performance:
-12.02%
6M Performance:
-17.18%
1Y Performance:
-13.03%
1-Day Range:
$23.00
$23.97
1-Week Range:
$22.29
$26.29
52-Week Range:
$18.35
$39.92
Xoma Royalty Corp Stock (XOMA) Company Profile
Name
Xoma Royalty Corp
Sector
Industry
Phone
510-204-7239
Address
2200 POWELL STREET, EMERYVILLE, CA
Compare XOMA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XOMA
Xoma Royalty Corp
|
23.57 | 288.15M | 9.71M | -29.96M | -14.79M | -3.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Xoma Royalty Corp Stock (XOMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-25 | Initiated | The Benchmark Company | Buy |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Sep-07-21 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-29-21 | Initiated | Aegis Capital | Buy |
| Jan-19-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-18-18 | Reiterated | H.C. Wainwright | Buy |
| Oct-17-17 | Resumed | H.C. Wainwright | Buy |
| Sep-05-17 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-12-17 | Initiated | H.C. Wainwright | Buy |
| Nov-14-16 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-11-16 | Reiterated | Wedbush | Outperform |
| Jul-23-15 | Downgrade | Jefferies | Buy → Hold |
| Jul-22-15 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-22-15 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Oct-10-14 | Resumed | ROTH Capital | Buy |
| Apr-29-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-11-14 | Downgrade | MLV & Co | Buy → Hold |
| Mar-05-14 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-31-13 | Reiterated | MLV & Co | Buy |
| May-09-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-14-12 | Initiated | Cowen & Co | Outperform |
| Mar-31-11 | Reiterated | MLV Capital | Buy |
| Mar-23-11 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-06-11 | Reiterated | Ladenburg Thalmann | Buy |
| Jan-04-11 | Reiterated | Wedbush | Outperform |
View All
Xoma Royalty Corp Stock (XOMA) Latest News
Xoma stock rating reinstated as Hold by TD Cowen after Generation Bio acquisition - Investing.com South Africa
Buyback Watch: What drives XOMA Royalty Corporations stock priceJuly 2025 Market Mood & Risk Controlled Stock Alerts - baoquankhu1.vn
XOMA Royalty (NASDAQ:XOMA) Upgraded at Zacks Research - Defense World
XOMA Royalty (NASDAQ:XOMA) Upgraded by Zacks Research to "Hold" Rating - MarketBeat
XOMA Royalty’s Preferreds Still Offer Compelling Income Despite Call Risk (NASDAQ:XOMA) - Seeking Alpha
Generation Bio pays landlord $21.5M to escape lease early after Xoma buyout - The Business Journals
XOMA Royalty completes acquisition of Generation Bio for $4.29 per share By Investing.com - Investing.com South Africa
XOMA Royalty completes acquisition of Generation Bio for $4.29 per share - Investing.com Nigeria
XOMA Royalty completes acquisition of Generation Bio; GBIO delisted from Nasdaq - Investing.com
XOMA Royalty Completes Generation Bio Acquisition and Merger - TipRanks
XOMA Royalty Corporation Completes Acquisition of Generation Bio Co. Through Tender Offer - Quiver Quantitative
Generation Bio investors cashed out at $4.2913 a share in XOMA takeover - Stock Titan
Published on: 2026-02-09 02:34:15 - baoquankhu1.vn
Gainers Report: What is the next catalyst for XOMA Royalty CorporationShare Buyback & Accurate Intraday Trading Signals - baoquankhu1.vn
Analysts Set XOMA Royalty Corporation (NASDAQ:XOMA) Target Price at $60.60 - Defense World
Short Interest in XOMA Royalty Corporation (NASDAQ:XOMA) Grows By 56.7% - MarketBeat
XOMA Royalty Corporation (NASDAQ:XOMA) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Analyzing XOMA Royalty (NASDAQ:XOMA) and Ascendis Pharma A/S (NASDAQ:ASND) - Defense World
Risk Off: What is the next catalyst for XOMA Royalty Corporation2025 Volume Leaders & Short-Term High Return Strategies - baoquankhu1.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - GlobeNewswire Inc.
Institutional owners may take dramatic actions as XOMA Royalty Corporation's (NASDAQ:XOMA) recent 12% drop adds to one-year losses - Yahoo Finance
Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty CorporationXOMA - marketscreener.com
XOMA Royalty Corp (NASDAQ: XOMA) appoints new CFO, sets pay terms - stocktitan.net
XOMA Royalty CFO Thomas Burns steps down, Jeffrey Trigilio appointed - Investing.com
XOMA royalty announces CFO transition - MSN
XOMA Royalty Corporation Announces CFO Transition as Thomas Burns Steps Down and Jeffrey Trigilio Takes Over - Quiver Quantitative
Biotech royalty firm XOMA shifts finance leadership after nearly 20 years - Stock Titan
XOMA Royalty Announces CFO Transition - The Manila Times
Is XOMA Royalty Corporation stock a defensive play in 20252025 Investor Takeaways & Reliable Price Breakout Signals - Улправда
Will XOMA Royalty Corporation (X0M1) stock profit from fiscal stimulus2026 world cup usa national team quarterfinals top scorers counter attacking tactical prediction breakdown - ulpravda.ru
Implied Volatility Surging for XOMA Royalty Stock Options - Yahoo Finance
XOMA Royalty Corporation (NASDAQ:XOMA) Given Average Rating of “Hold” by Analysts - Defense World
Takeda, XOMA ink new royalty agreement; amend existing deal - MSN
Xoma royalty corp sees sale of $16.98 million in stock by investors - MSN
Antibody Development Company Cleared to Pursue Royalties for Tremfya, Judge Rules - Law.com
Can XOMA Royalty Corporation stock double in next 5 yearsTechnical Analysis Insights & Free Trend Following Techniques - bollywoodhelpline.com
Leerink Partners reiterates Outperform rating on XOMA stock at $45 target - Investing.com India
XOMA and Takeda execute royalty sharing transaction - The Pharma Letter
Takeda regains majority of mezagitamab royalty interest from XOMA - Investing.com
XOMA Royalty: Entitled to Payments Associated - 富途牛牛
Drug royalties reshuffled as XOMA trades part of one for nine experimental drugs - Stock Titan
XOMA Royalty Corporation (NASDAQ:XOMA) Short Interest Up 31.7% in December - MarketBeat
XOMA Royalty (XOMAO) Stock Analysis Report | Financials & Insights - Benzinga
XOMA Royalty Declares Quarterly Preferred Stock Dividends - Sahm
XOMA Royalty Corporation Announces Cash Dividends for Preferred Stockholders - Quiver Quantitative
Two XOMA preferred share classes pay cash to holders in January - Stock Titan
Institutional Owners May Consider Drastic Measures as XOMA Royalty Corporation's (NASDAQ:XOMA) Recent US$57m Drop Adds to Long-term Losses - 富途牛牛
XOMA Royalty (NASDAQ:XOMA) shareholders have earned a 13% CAGR over the last three years - Yahoo Finance
Turnstone Biologics To Merge With Biotech Royalty Aggregator XOMA, But Retail Sentiment Slumps - MSN
Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO - RTTNews
Can XOMA Royalty Corporation stock deliver strong Q4 earningsRate Hike & Smart Investment Allocation Insights - Улправда
Xoma Royalty Corp Stock (XOMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):